AU2021330382A1 - Radiopharmaceutical and methods - Google Patents

Radiopharmaceutical and methods Download PDF

Info

Publication number
AU2021330382A1
AU2021330382A1 AU2021330382A AU2021330382A AU2021330382A1 AU 2021330382 A1 AU2021330382 A1 AU 2021330382A1 AU 2021330382 A AU2021330382 A AU 2021330382A AU 2021330382 A AU2021330382 A AU 2021330382A AU 2021330382 A1 AU2021330382 A1 AU 2021330382A1
Authority
AU
Australia
Prior art keywords
dotatate
amount
compounds
lutetium
octreotate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021330382A
Other languages
English (en)
Other versions
AU2021330382A9 (en
Inventor
Paul BILLONE
Justyna KELLY
Joe Mccann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre for Probe Development and Commercialization
Original Assignee
Centre For Probe Dev And Commercialization Cpdc
Centre for Probe Development and Commercialization
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre For Probe Dev And Commercialization Cpdc, Centre for Probe Development and Commercialization filed Critical Centre For Probe Dev And Commercialization Cpdc
Publication of AU2021330382A1 publication Critical patent/AU2021330382A1/en
Assigned to Centre for Probe Development and Commercialization (CPDC) reassignment Centre for Probe Development and Commercialization (CPDC) Amend patent request/document other than specification (104) Assignors: CENTRE FOR PROBE DEVELOPMENT ANDCOMMERCIALIZATION (CPDC)
Publication of AU2021330382A9 publication Critical patent/AU2021330382A9/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/083—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being octreotide or a somatostatin-receptor-binding peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/121—Solutions, i.e. homogeneous liquid formulation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2021330382A 2020-08-27 2021-08-27 Radiopharmaceutical and methods Pending AU2021330382A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063071138P 2020-08-27 2020-08-27
US63/071,138 2020-08-27
PCT/IB2021/000589 WO2022043754A2 (en) 2020-08-27 2021-08-27 Radiopharmaceutical and methods

Publications (2)

Publication Number Publication Date
AU2021330382A1 true AU2021330382A1 (en) 2023-05-04
AU2021330382A9 AU2021330382A9 (en) 2024-02-08

Family

ID=80352743

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021330382A Pending AU2021330382A1 (en) 2020-08-27 2021-08-27 Radiopharmaceutical and methods

Country Status (9)

Country Link
US (2) US11439714B2 (enExample)
EP (1) EP4204011A4 (enExample)
JP (1) JP2023540240A (enExample)
KR (1) KR20240121161A (enExample)
CN (1) CN116528904A (enExample)
AU (1) AU2021330382A1 (enExample)
CA (1) CA3190855A1 (enExample)
TW (1) TW202227143A (enExample)
WO (1) WO2022043754A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018204872A2 (en) * 2017-05-05 2018-11-08 Fusion Pharmaceuticals Inc. Igf-1r monoclonal antibodies and uses thereof
JP2023539990A (ja) 2020-07-13 2023-09-21 ポイント バイオファーマ インコーポレイテッド 放射性薬剤および方法
WO2023164769A1 (en) * 2022-03-02 2023-09-07 Point Biopharma, Inc. Radiopharmaceutical and methods
CN115015441B (zh) * 2022-07-14 2023-08-18 原子高科股份有限公司 一种测定镥[177Lu]氧奥曲肽注射液中稳定剂含量的方法
WO2025171492A1 (en) 2024-02-14 2025-08-21 Alpha-9 Oncology Inc. Stable radiopharmaceutical compositions and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1096278A (en) 1913-08-25 1914-05-12 American Radiator Co Service-outlet fitting for pneumatic cleaning systems.
US6066309A (en) 1996-02-02 2000-05-23 Rhomed Incorporated Post-labeling stabilization of radiolabeled proteins and peptides
US6358245B1 (en) 1998-02-19 2002-03-19 Curon Medical, Inc. Graphical user interface for association with an electrode structure deployed in contact with a tissue region
EP1596705B1 (en) 2003-02-05 2018-09-12 Arthrocare Corporation Temperature indicating electrosurgical apparatus
CN100418585C (zh) 2003-07-24 2008-09-17 伯拉考成像股份公司 稳定的放射性药物组合物及制备方法
HK1254404A1 (zh) * 2015-06-25 2019-07-19 Advanced Accelerator Applications 治疗过度表达生长抑素受体的神经内分泌肿瘤的方法
CN115089242A (zh) 2016-05-23 2022-09-23 Ip2Ipo创新有限公司 末端执行器和持针器
US10537399B2 (en) 2016-08-16 2020-01-21 Ethicon Llc Surgical tool positioning based on sensed parameters
US10537394B2 (en) 2016-12-19 2020-01-21 Ethicon Llc Hot device indication of video display
US20200030466A1 (en) * 2018-07-25 2020-01-30 Advanced Accelerator Applications (Italy) Srl Stable, concentrated radionuclide complex solutions
US10596276B2 (en) * 2018-07-25 2020-03-24 Advanced Accelerator Applications (Italy) S.R.L. Stable, concentrated radionuclide complex solutions
WO2020064693A1 (en) * 2018-09-25 2020-04-02 Advanced Accelerator Applications (Italy) Srl Combination therapy
CN112969675B (zh) * 2018-10-31 2024-12-20 意大利国际先进加速器应用有限公司 用于合成放射性核素络合物的方法

Also Published As

Publication number Publication date
US20220387637A1 (en) 2022-12-08
WO2022043754A2 (en) 2022-03-03
US20220062447A1 (en) 2022-03-03
EP4204011A4 (en) 2025-06-18
TW202227143A (zh) 2022-07-16
WO2022043754A3 (en) 2022-04-07
CN116528904A (zh) 2023-08-01
CA3190855A1 (en) 2022-03-03
US11439714B2 (en) 2022-09-13
AU2021330382A9 (en) 2024-02-08
JP2023540240A (ja) 2023-09-22
EP4204011A2 (en) 2023-07-05
KR20240121161A (ko) 2024-08-08

Similar Documents

Publication Publication Date Title
US11439714B2 (en) Radiopharmaceutical and methods
US20230302163A1 (en) Radiopharmaceutical and methods
US11129912B1 (en) Radiopharmaceutical and methods
US20090155167A1 (en) Automated method
Ballinger Pitfalls and limitations of SPECT, PET, and therapeutic radiopharmaceuticals
EP1307239B1 (en) Radiopharmaceutical for diagnostic imaging containing a technetium-99m nitride heterocomplex
JP7804652B2 (ja) ６４Ｃｕ－ＤＯＴＡＴＡＴＥのスケールアップのための放射標識および製剤化
CN116547007A (zh) 放射性药物和方法
WO2023164769A9 (en) Radiopharmaceutical and methods
HK40088578A (en) Radiopharmaceutical and methods
CN118742332A (zh) 放射性药物和方法
US11723992B2 (en) Method for extraction and purification of 68GA
CN103153349A (zh) 用于治疗人类肝癌的基于铼-188的组合物和制备这种组合物的方法
LijuanáChen et al. GMP-compliant automated radiosynthesis of [18 F] SynVesT-1 for PET imaging of synaptic vesicle glycoprotein 2áA (SV2A)
Nanabala et al. Preparation of Patient Doses of [177Lu] Lu‑DOTATATE and [177Lu] Lu‑PSMA‑617 with Carrier Added (CA) and No Carrier Added (NCA)
HK1134901A1 (en) Radioactive diagnostic imaging agent
HK1134901B (en) Radioactive diagnostic imaging agent

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: CENTRE FOR PROBE DEVELOPMENT AND COMMERCIALIZATION (CPDC)

Free format text: FORMER NAME(S): CENTRE FOR PROBE DEVELOPMENT ANDCOMMERCIALIZATION (CPDC)

SREP Specification republished